Beneficial effects of protocatechuic acid on diabetic retinopathy in streptozocin-induced diabetic rats.

diabetic retinopathy oxidative stress protocatechuic acid streptozocin vascular endothelial growth factor

Journal

International journal of ophthalmology
ISSN: 2222-3959
Titre abrégé: Int J Ophthalmol
Pays: China
ID NLM: 101553860

Informations de publication

Date de publication:
2023
Historique:
received: 03 02 2023
accepted: 04 04 2023
medline: 19 6 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: epublish

Résumé

To determine the effects of protocatechuic acid (PCA) on streptozocin-induced diabetic retinopathy (DR) in rats. Wistar rats were given a 50 mg/kg intraperitoneal injection of streptozocin to induce diabetes. Animals were assigned randomly one of four groups (8 rats per group): control, diabetic, diabetic plus PCA (25 mg/kg·d), and diabetic plus PCA (50 mg/kg·d). After inducing diabetes, treatments were started one week later and continued for eight weeks. After the experiment, the rats were sacrificed, and their retinas were taken for biochemical and molecular analysis. PCA administration diminished the blood glucose and glycated haemoglobin levels relative to the diabetic group. In diabetic rats, PCA lowered elevated levels of advanced glycosylated end products (AGEs) and receptor for AGEs (RAGE). In the retina of diabetic rats, PCA effectively decreased inflammatory cytokine, nuclear factor-κB, tumour necrosis factor-α, interleukin-1β, and vascular endothelial growth factor, and increased antioxidant markers glutathione, superoxide dismutase, and catalase. The protective benefits of PCA against DR may be attributable to its suppression of the AGEs and RAGE and its antioxidant and anti-inflammatory properties.

Identifiants

pubmed: 37332540
doi: 10.18240/ijo.2023.06.04
pii: ijo-16-06-855
pmc: PMC10250939
doi:

Types de publication

Journal Article

Langues

eng

Pagination

855-862

Informations de copyright

International Journal of Ophthalmology Press.

Références

Diabetes Metab Syndr Obes. 2020 Jun 24;13:2179-2187
pubmed: 32636659
Sci Rep. 2022 Sep 23;12(1):15872
pubmed: 36151457
Am J Pathol. 2021 May;191(5):947-964
pubmed: 33640319
Molecules. 2016 Dec 11;21(12):
pubmed: 27973425
Cells. 2020 Jun 11;9(6):
pubmed: 32545222
Anal Biochem. 1979 Jun;95(2):351-8
pubmed: 36810
Biochem Biophys Res Commun. 2021 Apr 9;548:27-34
pubmed: 33631670
Bull Exp Biol Med. 2021 May;171(2):179-189
pubmed: 34173093
Redox Biol. 2020 Oct;37:101799
pubmed: 33248932
Cells. 2022 Jan 31;11(3):
pubmed: 35159301
Signal Transduct Target Ther. 2020 Sep 21;5(1):209
pubmed: 32958760
Toxicology. 2020 Sep;442:152556
pubmed: 32758512
Methods Enzymol. 1984;105:121-6
pubmed: 6727660
Curr Diabetes Rev. 2019;15(5):363-371
pubmed: 30332969
Lancet Diabetes Endocrinol. 2020 Apr;8(4):337-347
pubmed: 32113513
Arch Toxicol. 2003 Jan;77(1):42-7
pubmed: 12491040
Nutrients. 2022 Jan 12;14(2):
pubmed: 35057488
ISRN Pharmacol. 2014 Mar 26;2014:952943
pubmed: 25006494
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5594-5603
pubmed: 29084332
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724805
Diabetologia. 2018 Jan;61(1):29-38
pubmed: 28942458
Eye (Lond). 2018 Jun;32(6):1010-1020
pubmed: 29398697
Biochem Med (Zagreb). 2020 Oct 15;30(3):030502
pubmed: 32774120
Oxid Med Cell Longev. 2016;2016:3164734
pubmed: 26881021
Eye Vis (Lond). 2015 Sep 30;2:17
pubmed: 26605370
Evid Based Complement Alternat Med. 2015;2015:593902
pubmed: 25737736
Wound Repair Regen. 2019 Jul;27(4):324-334
pubmed: 30817065
Rep Biochem Mol Biol. 2022 Oct;11(3):394-399
pubmed: 36718309
Exp Eye Res. 2019 Apr;181:356-366
pubmed: 30503749
J Diabetes Complications. 2021 Aug;35(8):107946
pubmed: 34053797
Clin Chim Acta. 2018 Oct;485:210-217
pubmed: 29959897
Pharmacol Res. 2020 Nov;161:105109
pubmed: 32738494
Diabetes Care. 2022 Jan 1;45(1):127-133
pubmed: 34716212
J Basic Clin Physiol Pharmacol. 2010;21(1):79-91
pubmed: 20506690
Chin Med. 2020 Jan 14;15:5
pubmed: 31956338
Front Immunol. 2020 Nov 06;11:583687
pubmed: 33240272
Clin Chem. 1975 Nov;21(12):1754-60
pubmed: 1237363
Cell Death Dis. 2018 Jan 25;9(2):119
pubmed: 29371661
Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):3-16
pubmed: 29376231

Auteurs

Ling Wan (L)

Department of Ophthalmology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan Province, China.
Department of Ophthalmology, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, Sichuan Province, China.

Jun Li (J)

Department of Ophthalmology, the First People's Hospital of Lanzhou City, Lanzhou 730050, Gansu Province, China.

Wei-Bai Chen (WB)

Department of Ophthalmology, the First People's Hospital of Lanzhou City, Lanzhou 730050, Gansu Province, China.

Guo-Qiang Wu (GQ)

Department of Ophthalmology, the First People's Hospital of Lanzhou City, Lanzhou 730050, Gansu Province, China.

Classifications MeSH